Asset Details
Do you wish to reserve the book?
Early treatment-related neutropenia predicts response to palbociclib
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Early treatment-related neutropenia predicts response to palbociclib
Do you wish to request the book?
Early treatment-related neutropenia predicts response to palbociclib
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Early treatment-related neutropenia predicts response to palbociclib
2020
Overview
Background
Palbociclib is highly active in oestrogen-receptor positive (ER+) metastatic breast cancer, but neutropenia is dose limiting. The goal of this study was to determine whether early neutropenia is associated with disease response to single-agent palbociclib.
Methods
Blood count and disease-response data were analysed from two Phase 2 clinical trials at different institutions using single-agent palbociclib: advanced solid tumours positive for retinoblastoma protein and advanced liposarcoma. The primary endpoint was PFS. The primary exposure variable was the nadir absolute neutrophil count (ANC) during the first two cycles of treatment.
Results
One hundred and ninety-six patients (61 breast, 135 non-breast) were evaluated between the two trials. Development of any grade neutropenia was significantly associated with longer median PFS in both the breast cancer (HR 0.29, 95% CI 0.11–0.74,
p
= 0.010) and non-breast cancer (HR 0.57, 95% CI 0.38–0.85,
p
= 0.006) cohorts. Grade 3–4 neutropenia was significantly associated with prolonged PFS in the non-breast cohort (HR 0.57, 95% CI 0.38–0.85,
p
= 0.006) but not in the breast cohort (HR 0.87, 95% CI 0.51–1.47,
p
= 0.596). Multivariate analysis yielded similar results.
Conclusions
Treatment-related neutropenia in the first two cycles was significantly and independently associated with prolonged PFS, suggesting that neutropenia may be a useful pharmacodynamic marker to guide individualised palbociclib dosing.
Clinical trials registration information
Basket Trial: NCT01037790; Sarcoma Trial: NCT01209598.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Biomedical and Life Sciences
/ Cancer
/ Cyclin-Dependent Kinase 4 - antagonists & inhibitors
/ Cyclin-Dependent Kinase 6 - antagonists & inhibitors
/ Dosage
/ Female
/ Humans
/ Male
/ Neutropenia - chemically induced
/ Oncology
/ Piperazines - adverse effects
/ Protein Kinase Inhibitors - adverse effects
/ Retina
